Archive · 8 Jan 2026
Sun Pharma's SPARC Cuts Workforce by 40 Percent
Sun Pharma's research company, SPARC, is reducing its workforce by 40 percent.
This means they will have fewer employees by the year 2027.
They are also changing how they do their work, by outsourcing some of it to other companies.
This change is not because of problems in the US, but because a product they expected to do well did not.
The company has saved $10 million each year and has a debt of $46 million.
They are planning to use more debt and their own money to support their research in the future.
Sun Pharma Advanced Research Company Ltd (Sparc) is reducing its workforce by 40 percent, primarily in the US.
The projected workforce by FY27 is 246 employees, down from 409 in FY24.
Laboratory operations will be consolidated from four locations to two, between Vadodara and Mumbai.
The company has achieved $10 million in annual savings through focused cost optimization.
Sparc is shifting to a hybrid business model, partly outsourcing research work to clinical research organizations.
- Who
- Sun Pharma Advanced Research Company Ltd (Sparc)
- What
- Reduction of workforce by 40 percent and shift to a hybrid business model
- When
- The reduction has been happening over a three-year period, with a projected workforce of 246 by FY27
- Where
- Primarily in the US, with laboratory operations consolidating from four locations to two (Vadodara and Mumbai)
- Why
- To achieve focused cost optimization, strengthen operational efficiency, and improve long-term financial sustainability
- Company
- Sun Pharma Advanced Research Company Ltd (Sparc)
- Workforce Reduction
- 40 percent
- Projected Workforce by FY27
- 246 employees
- Current Workforce (FY24)
- 409 employees
- Annual Savings
- $10 million
- Outstanding Debt
- $46 million
- Total Income (March 2025)
- ₹71 crore
- Approved Debt Limit
- $125 million